Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 30, 2002

Study Completion Date

March 31, 2003

Conditions
Ovarian Neoplasms
Interventions
DRUG

OSI-211 (Liposomal Lurtotecan)

Trial Locations (11)

10016

NYU- Kaplan Comprehensive Cancer Center, New York

37203

The Sarah Cannon Cancer Center, Centennial Medical Center, Nashville

B18 7QH

St Chad's Unit, Birmingham

G11 6NT

Beatson Oncology Centre, Glasgow

GU2 7XX

Royal Surrey County Hospital, Guildford, Surrey

SW3 6JJ

Royal Marsden NHS Trust, London

NE4 6BE

Northern Centre for Cancer Research, Newcastle General Hospital, Newcastle upon Tyne

HA6 2RN

Mount Vernon Hospital, Northwood, Middlesex

SM2 5PT

CRC Department of Medical Oncology, Sutton Surrey

TA1 5DA

Taunton & Somerset Hospital, Taunton

TQ2 7AA

Medical Oncology Unit, Torbay District General Hospital, Torquay

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

OSI Pharmaceuticals

INDUSTRY

lead

Astellas Pharma Inc

INDUSTRY